HM 95573

Drug Profile

HM 95573

Alternative Names: HM95573; RG 6185

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action Proto oncogene protein b raf inhibitors; Proto oncogene proteins c raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 22 May 2017 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in South Korea (PO) (NCT03284502)
  • 21 Apr 2017 Hanmi Pharmaceutical plans a phase I trial for Solid tumours (Monotherapy) in South Korea (NCT03118817)
  • 29 Sep 2016 Hanmi Pharmaceutical enters into an license agreement with Genentech to obtain worldwide rights, excluding South Korea for HM 95573
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top